Preview

Эффективность применения препарата Роглит у больных сахарным диабетом 2 типа

https://doi.org/10.14341/2071-8713-5330

Полный текст:

Список литературы

1. Cefalu W.T. Insulin resistance: cellular and clinical concepts.// Experimental Biology and Medicine. - 2001; 226: 13-26.

2. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files.// Sciense.- 2001; 294 (5548): 1866-1870.

3. Cheng A.Y.Y., Fantus I.G. Oral antihyperglycemic therapy for type 2 diabetes mel-litus. //Can. Med. Assoc. J. - 2005;172(2): 213-226.

4. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. //Endocr. Rev. -1999; 20: 649-688.

5. Ferre` P. The biology of peroxisome proliferator-activated receptors. Relationship with lipid metabolism and insulin sensitivity.// Diabetes. - 2004; 53: 43-50.

6. H. Yki-Jarvinen. Thiazolidinediones. // N. Engl. J. Med. - 2004; 351(11): 1106-1118.

7. Jiang, C., Ting, A.T. & Seed, B. PPAR- agonists inhibit production of monocyte inflammatory cytokines.// Nature. - 2001; 391: 82-86.

8. Kintscher U., Law R.E. PPAR{gamma}-mediated insulin sensitization: the importance of fat versus muscle.//Am. J. Physiol. Endocrinol. Metab. - 2005; 288(2): 287-291.

9. Lebovitz H.E., Dole J.F., Patwardhan R. et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. //J. Clin. Endocrinol. Metab. - 2001; 86: 280-288.

10. Lee C., Olson P., Ronald M. Evans R. M. Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors.// Endocrinology. - 2003; 144 (6): 2201-2207.

11. Madan P. Effect of thiazolidinediones on lipid profile. //Can. Med. Assoc. J., August 16, 2005; 173(4): 344-344.

12. Maeda N., Takahashi M., Funahashi T. et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived pro-tein.// Diabetes.- 2001; 50: 2094-2099.

13. Nissen S.E, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. // N. Engl. J. Med. - 2007; 356(24): 2457-2471.

14. Rosen E.D., Spiegelman B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth.// J. Biol. Chem. - 2001; 276: 37731-37734.

15. Schiffrin E. L., Amiri F., Benkirane K. Et al. Peroxisome proliferator-activated receptors. Vascular and cardiac effects in hypertension. //Hypertension. - 2003; 42: 664-672.

16. Shao D., Lazar M. A. Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation.// J. Biol. Chem. -1997; 272: 21473-21478.

17. van Wijk J. P.H., de Koning E. J.P; Martens E. P.; Rabelink J.T. Thiazolidinediones and blood lipids in type 2 diabetes. //Arteriosclerosis, Thrombosis, and Vascular Biology. - 2003; 23:1744-1750.

18. Walczak R., Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism.// J. Lipid. Res. - 2002; 43: 177-186.

19. Willson T.M., Lambert M.H., Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. //Annu. Rev. Biochem. - 2001; 70: 341-367.

20. Yu J.G., Javorschi S., Hevener A.L. et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. //Diabetes. - 2002; 5: 2968-2974.


Для цитирования:


Romantsova T.I., Volkova G.E., Roik O.V., Poluboyarinova I.V. Эффективность применения препарата Роглит у больных сахарным диабетом 2 типа. Ожирение и метаболизм. 2008;5(3):7-12. https://doi.org/10.14341/2071-8713-5330

For citation:


., ., ., . Effektivnost' primeneniya preparata Roglit u bol'nykh sakharnym diabetom 2 tipa. Obesity and metabolism. 2008;5(3):7-12. (In Russ.) https://doi.org/10.14341/2071-8713-5330

Просмотров: 4


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)